Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Sep;30(9):7645-7653.
doi: 10.1007/s00520-022-07184-2. Epub 2022 Jun 9.

Randomized trial of sucrosomial iron supplementation in patients with chemotherapy-related anemia treated with ESA

Andrea Zuccarini #  1 , Daniela Cicognini #  1 , Richard Tancredi #  2 , Alessandra Ferrari  1 , Gianpiero Rizzo  2 , Angioletta Lasagna  2 , Riccardo Caccialanza  3 , Luigi Cavanna  4 , Elena Orlandi  4 , Claudia Biasini  4 , Peppina Molinaro  5 , Danula Garigliano  5 , Angela Costantino  5 , Mauro Moroni  6 , Lorenzo Perrone  2 , Niccolò Leandro Alessio  2 , Bianca Rovati  1 , Virginia Valeria Ferretti  7 , Catherine Klersy  7 , Paolo Pedrazzoli  8   9
Affiliations
Clinical Trial

Randomized trial of sucrosomial iron supplementation in patients with chemotherapy-related anemia treated with ESA

Andrea Zuccarini et al. Support Care Cancer. 2022 Sep.

Abstract

Background: Iron supplementation improves the erythropoiesis-stimulating agents' (ESAs) response in chemotherapy-related anemia. The primary aim of our study is to assess the efficacy of sucrosomial iron, a new oral iron formulation, in cancer patients with chemotherapy-induced anemia treated with ESAs. The secondary objectives included the efficacy into two subgroups of patients (iron replete and functional iron deficiency) between the two study arms, safety and the effect on transfusion need.

Methods: In this randomized, multicentre, open-label, phase III clinical trial, 60 cancer patients were enrolled. Each patient was randomly assigned (1:1) to receive 12 weeks of oral sucrosomial iron at the dose of 30 mg daily in combination with ESAs or no supplementation to ESA treatment. The endpoint considered for efficacy was the proportion of patients achieving complete hematological response at 12 weeks (increase in Hb > 2 g/dL from baseline, without RBC transfusions in the previous 28 days or achieving Hb ≥ 12 g/dL).

Results: There was a statistically significant association between oral sucrosomial iron supplementation in combination with ESAs and the achievement of a complete hematological response. This response was achieved within 12 weeks by 31% of patients in the control group and by 52% of patients supplemented with oral sucrosomial iron. A trend of greater response in sucrosomial iron arm was found in both subgroups. No difference was observed about safety and transfusion need.

Conclusions: Sucrosomial iron is well tolerated and its combination with ESAs improves the hematological response in cancer patients with chemotherapy-related anemia.

Trial registration number and date of registration: This study has been reviewed by the Institutional Ethics Committee of the IRCCS Policlinico San Matteo Foundation, Pavia, Italy (28/04/2015; prot. N. 20,150,002,059), and by the Institutional Ethics Committee of the other Italian oncological centers involved in this study.

Keywords: Chemotherapy-related anemia; Complete hematological response; ESAs; Sucrosomial iron.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Rodgers GM III et al (2012) Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw 10(5):628–653. https://doi.org/10.6004/jnccn.2012.0064 - DOI - PubMed
    1. Melosky BL (2008) Erythropoiesis-stimulating agents: benefits and risks in supportive care of cancer. Curr Oncol 15(Suppl 1):S10–S15. https://doi.org/10.3747/co.2008.172 - DOI - PubMed - PMC
    1. Bohlius J, et al (2006) Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev (3):CD003407. https://doi.org/10.1002/14651858.CD003407.pub4
    1. Escobar Álvarez Y et al (2021) SEOM clinical guidelines for anaemia treatment in cancer patients (2020). Clin Transl Oncol 23(5):931–939. https://doi.org/10.1007/s12094-021-02580-2 - DOI - PubMed - PMC
    1. Pedrazzoli P et al (2009) Iron supplementation and erythropoiesis-stimulatory agents in the treatment of cancer anemia. Cancer 115(6):1169–1173. https://doi.org/10.1002/cncr.24115 - DOI - PubMed

Publication types

LinkOut - more resources